{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T02:18:25Z","timestamp":1795141105704,"version":"4.10.3"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Foundation for the National Institutes of Health","award":["R01-EY031315"],"award-info":[{"award-number":["R01-EY031315"]}],"id":[{"id":"https:\/\/ror.org\/00k86s890","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Research to Prevent Blindness","award":["Unrestricted Grant"],"award-info":[{"award-number":["Unrestricted Grant"]}],"id":[{"id":"https:\/\/ror.org\/04drjs621","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Inflammatory cytokines are key mediators of diabetic macular edema (DME). Prior assessments are limited by study design and small sample size. We rigorously analyzed the association of 24 inflammatory cytokines with DME in a prospective trial of 328 eyes of 164 adult type II diabetic patients with different stages of diabetic retinopathy severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Early Treatment Diabetic Retinopathy Study visual acuity, fundus photography, and optical coherence tomography (OCT) of each eye were taken at baseline. Bilateral aqueous sampling was performed. A microparticle bead-based multiplex assay was used to measure aqueous levels of 24 inflammatory cytokines. Diabetic macular edema was defined as central subfield thickness &gt;320\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m on OCT with the presence of intraretinal fluid.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Median and interquartile range of vascular endothelial growth factor A, IL-6, and IL-8 were 148.70 pg\/mL (103.93\u2013232.96), 7.67 pg\/mL (4.64\u201318.90), and 11.14 pg\/mL (6.48\u201317.46) in eyes without DME, respectively, and 181.32 pg\/mL (141.82\u2013307.81), 16.53 pg\/mL (8.15\u201348.68), and 15.95 (10.67\u201326.53) in eyes with DME, respectively. Positive odds ratios with 95% confidence intervals were observed for IL-8 (2.73 [1.41\u20135.29];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003), FMS-like tyrosine kinase 3 ligand (FLT-3L) (2.27 [1.22\u20134.23];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01), FGF-2 (1.74 [1.06\u20132.86];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.029), IL-6 (2.93 [1.62\u20135.31];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), and IL-10 (2.79 [1.50\u20135.21];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We report that IL-8, FLT-3L, FGF-2, IL-6, and IL-10 were significantly elevated in eyes with DME.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004893","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:01:21Z","timestamp":1780668081000},"page":"1513-1519","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["INFLAMMATORY MEDIATORS IN DIABETIC MACULAR EDEMA"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7861-1563","authenticated-orcid":false,"given":"Stephen J.","family":"Kim","sequence":"first","affiliation":[{"name":"Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna","family":"Gangaputra","sequence":"additional","affiliation":[{"name":"Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"McNeer","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Sheng","sequence":"additional","affiliation":[{"name":"Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20261120","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0161-6420(95)31052-4","article-title":"The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema","volume":"102","author":"Klein","year":"1995","journal-title":"Ophthalmology"},{"key":"R3-20261120","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.ophtha.2015.03.024","article-title":"Diabetic macular edema: pathophysiology and novel therapeutic targets","volume":"122","author":"Das","year":"2015","journal-title":"Ophthalmology"},{"key":"R4-20261120","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1097\/IAE.0b013e3181e095c0","article-title":"Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab","volume":"30","author":"Funk","year":"2010","journal-title":"Retina"},{"key":"R5-20261120","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamaophthalmol.2015.5346","article-title":"Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment","volume":"134","author":"Bressler","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"R6-20261120","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ophtha.2021.07.009","article-title":"Intravitreal pharmacotherapies for diabetic macular edema: a report by the American academy of ophthalmology","volume":"129","author":"Ehlers","year":"2022","journal-title":"Ophthalmology"},{"key":"R7-20261120","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"key":"R8-20261120","first-page":"9402198","article-title":"Association between aqueous cytokines and diabetic retinopathy stage","volume":"2017","author":"Wu","year":"2017","journal-title":"J Ophthalmol"},{"key":"R9-20261120","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1111\/aos.14891","article-title":"Changes in aqueous and vitreous inflammatory cytokine levels in diabetic macular oedema: a systematic review and meta-analysis","volume":"100","author":"Minaker","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"R10-20261120","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/s41433-024-03015-2","article-title":"Aqueous humor interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy","volume":"38","author":"Sepah","year":"2024","journal-title":"Eye (Lond)"},{"key":"R11-20261120","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap) \u2013 a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"R12-20261120","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"R13-20261120","doi-asserted-by":"crossref","first-page":"20","DOI":"10.26502\/fjor.2644-002400101","article-title":"Inflammatory mediators in the pathophysiology of diabetic retinopathy (INSPIRE): study design and baseline characteristics","volume":"8","author":"Gangaputra","year":"2025","journal-title":"J Ophthalmol Res"},{"key":"R14-20261120","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0161-6420(03)00475-5","article-title":"Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales","volume":"110","author":"Wilkinson","year":"2003","journal-title":"Ophthalmology"},{"key":"R15-20261120","doi-asserted-by":"crossref","first-page":"8154","DOI":"10.1167\/iovs.12-10290","article-title":"Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg spectralis optical coherence tomography","volume":"53","author":"Chalam","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R16-20261120","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"R17-20261120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/8164250","article-title":"Role of inflammation in classification of diabetic macular edema by optical coherence tomography","volume":"2019","author":"Chung","year":"2019","journal-title":"J Diabetes Res"},{"key":"R18-20261120","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1167\/iovs.12-10410","article-title":"Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines","volume":"53","author":"Schoenberger","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R19-20261120","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1167\/iovs.10-6319","article-title":"Reduced choroidal neovascular membrane formation in cyclooxygenase-2 null mice","volume":"52","author":"Rezaei","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R20-20261120","doi-asserted-by":"crossref","first-page":"101003","DOI":"10.1016\/j.xops.2025.101003","article-title":"INflammatory MediatorS in the PathophysIology of diabetic REtinopathy study: baseline analysis of 24 aqueous cytokines","volume":"6","author":"Kim","year":"2025","journal-title":"Ophthalmol Sci"},{"key":"R21-20261120","doi-asserted-by":"crossref","first-page":"583687","DOI":"10.3389\/fimmu.2020.583687","article-title":"The role of inflammation in diabetic retinopathy","volume":"11","author":"Forrester","year":"2020","journal-title":"Front Immunol"},{"key":"R22-20261120","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.preteyeres.2011.05.002","article-title":"Inflammation in diabetic retinopathy","volume":"30","author":"Tang","year":"2011","journal-title":"Prog Retin Eye Res"},{"key":"R23-20261120","first-page":"281981","article-title":"Nonsteroidal anti-inflammatory drugs for retinal disease","volume":"2013","author":"Schoenberger","year":"2013","journal-title":"Int J Inflamm"},{"key":"R24-20261120","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s11892-013-0382-z","article-title":"Soluble mediators of diabetic macular edema: the diagnostic role of aqueous VEGF and cytokine levels in diabetic macular edema","volume":"13","author":"Owen","year":"2013","journal-title":"Curr Diab Rep"},{"key":"R25-20261120","doi-asserted-by":"crossref","first-page":"e2004433","DOI":"10.1002\/advs.202004433","article-title":"Cytokines: from clinical significance to quantification","volume":"8","author":"Liu","year":"2021","journal-title":"Adv Sci"},{"key":"R26-20261120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamaophthalmol.2013.6203","article-title":"Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy","volume":"132","author":"Schoenberger","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R27-20261120","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/APO.0000000000000468","article-title":"Optical coherence tomography classification systems for diabetic macular edema and their associations with visual outcome and treatment responses - an updated review","volume":"11","author":"Hui","year":"2022","journal-title":"Asia-Pacific J Ophthalmol"},{"key":"R28-20261120","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.3390\/jcm12165232","article-title":"Normative data for macular thickness and volume for optical coherence tomography in a diabetic population without maculopathies","volume":"12","author":"Arruabarrena","year":"2023","journal-title":"J Clin Med"},{"key":"R29-20261120","doi-asserted-by":"crossref","first-page":"956795","DOI":"10.3389\/fimmu.2022.956795","article-title":"Interleukin-6 inhibition in the treatment of autoinflammatory diseases","volume":"13","author":"Koga","year":"2022","journal-title":"Front Immunol"},{"key":"R30-20261120","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1136\/bjo-2024-326006","article-title":"Simultaneous inhibition of fibroblast growth factor-2 and vascular endothelial growth factor-a with RC28-E in diabetic macular edema: a phase 2 randomised trial","volume":"109","author":"Zhang","year":"2025","journal-title":"Br J Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T02:00:16Z","timestamp":1795140016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004893"}},"subtitle":["A Prospective, Controlled Study"],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004893","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}